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Discoveries from basic science research in the last decade have brought signiﬁcant progress in knowl-
edge of pathophysiologic processes of allergic diseases, with a compelling impact on understanding of
the natural history, risk prediction, treatment selection or mechanism-speciﬁc prevention strategies. The
view of the pathophysiology of allergic diseases developed from a mechanistic approach, with a focus on
symptoms and organ function, to the recognition of a complex network of immunological pathways.
Several subtypes of inﬂammation and complex immune-regulatory networks and the reasons for their
failure are now described, that open the way for the development of new diagnostic tools and innovative
targeted-treatments. An endotype is a subtype of a disease condition, which is deﬁned by a distinct
pathophysiological mechanism, whereas a disease phenotype deﬁnes any observable characteristic of a
disease without any implication of a mechanism. Another key word linked to disease endotyping is
biomarker that is measured and evaluated to examine any biological or pathogenic processes, including
response to a therapeutic intervention. These three keywords will be discussed more and more in the
future with the upcoming efforts to revolutionize patient care in the direction of precision medicine and
precision health. The understanding of disease endotypes based on pathophysiological principles and
their validation across clinically meaningful outcomes in asthma, allergic rhinitis, chronic rhinosinusitis,
atopic dermatitis and food allergy will be crucial for the success of precision medicine as a new approach
to patient management.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).nology, Faculty of Medicine, Transylvania University, Bvd. Eroilor nr 29, Brasov 500030, Romania.
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The three key words endotype, phenotype and biomarker will
be one of the main topics of research on the way of building blocks
of precision medicine and precision health.1e3 The word “endo-
type” uncovers molecular mechanisms underlying observable dis-
ease characteristics known as “phenotype”.4,5 Assigning unique
mechanisms and biomarkers for each endotype is crucial for the
validity of the endotype.5,6 So far only few (if any) valid endotypes
have been identiﬁed in allergic disease, all with therapeutic im-
plications. To further elaborate on the deﬁnition of an endotype one
must recognize that one major pathogenic pathway such as type 2
immune response is highly complex, including several de-
terminants with nonlinear dynamic interactions (Fig. 1) and het-
erogeneous, since not all determinants are present in all patients or,
in a given patient, at all time points.6,7 We therefore must embrace
the concept of a “complex endotype” consisting of several sub-
endotypes as opposed to an endotype that encompasses a single
molecular mechanism.7Disease e
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factors and metabolic pathways.Epigenetics and endotypes of allergy and asthma
Epigenetic programming during early life inﬂuences is crucial
for the development of the endotypes of allergic diseases. Increased
knowledge on developmental endotypes addressing disease
inception and progression are needed for the outset of early pre-
vention and disease modifying strategies. Crucial determining
factors for complex immune regulation and barrier function
include respiratory infections, microbiome, and nutrition. Epige-
netic mechanisms link gene regulation to environmental inﬂuences
and developmental trajectories.8 Developmental programming
induced by the intrauterine environment (cigarette smoke, nutri-
tion, and stress) affects the fetus and its germ line, with intergen-
erational epigenetic effects. Developmental programming can be
transmitted across generations (trans-generational effects) and
cannot be anymore attributed to direct environmental exposure.
Several time-dependent DNA methylation signatures associated
with allergic disease developmental endotypes are described. The
Tucson Infant Immune Study identiﬁed in cord blood mononuclear
cells 589 differentially methylated regions associated withndotype 
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in allergic disease, more mechanistic approaches are needed, based on an integrated
tween the immune response and the exposome, infections and microbiome, genetics,
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immunoregulatory and pro-inﬂammatory pathways.9 Examination
of the methylome of children with or without food sensitization at
birth and 12 months revealed a novel 92-CpG signature in CD4 T
cells, enriched in genes encoding MAP kinase signaling molecules,
distinguishing children who developed clinical food allergy by age
12 months. This signature was stable from birth until 12 months of
age, suggesting that the children bearing that signature were on an
epigenetic path to disease already at birth.10 DNA methylation
could mechanistically explain the effect of season of birth on al-
lergy. In a subset of participants from the Isle of Wight birth cohort
autumn birth increased risk of eczema, relative to spring birth.
Methylation status of 92 CpGs showed association with season of
birth. Results were validated in the Prevention and Incidence of
Asthma and Mite Allergy (PIAMA) cohort and showed signiﬁcantly
more CpGs with the same directionality than expected by chance,
and four were statistically signiﬁcant. Season-associated methyl-
ation was enriched among networks relating to development, the
cell cycle, and apoptosis. Twenty CpGs were nominally associated
with allergic outcomes. Season-associated methylation was absent
in newborns, suggesting it appears postnatal.11 DNA methylation
marks involved in T-cell maturation (RUNX3), type 2 immune
response (IL4), and oxidative stress (catalase) were associated with
allergic asthma in the inner city study.12 In monozygotic twin pairs
with discordance for asthma symptoms methylomic markers in
peripheral blood differentiate remitting and persisting asthma.13
Peripheral blood readily detectable DNA methylomic biomarkers
outperformed allergen-speciﬁc IgE and skin prick tests for pre-
dicting food challenge outcomes.14
Biomarkers, precision medicine and endotypes
Biomarkers, or biological markers, are measurable indicators
used to examine any aspects of health or disease. Any type of an-
alyses can be a biomarker and may provide information about the
pathophysiology of an underlying disease, the course of an illness,
and/or the response to treatment. They are expected to inform us if
a disease is present or absent, deﬁne its severity, provide infor-
mation about its progression, serve to select most effective treat-
ment, and/or serve as guidance about the affected individual's
survival. Biomarkers are used at present to predict treatment
response and very few to forecast disease risk and progression. It
should be noted that most biomarkers are currently suited only for
research settings and still need to be validated and qualiﬁed.15e17
Steps towards biomarker qualiﬁcation are clearly delineated by
regulators lead by the FDA.18 At present, biomarkers are not sufﬁ-
ciently speciﬁc to select the endotype speciﬁcally responding to a
targeted treatment. For example, blood eosinophils predict
response to anti-IL-4/IL-13, anti-IL-5, and anti-IgE antibodies, as
well as CRTH2 antagonists and the clinician will face a challenge of
how best to treat severe asthma patients with high blood
eosinophils.3,17
Precision medicine represents a novel approach, embracing
four key features: personalized care based on molecular, immu-
nologic and functional endotyping of the disease, with participa-
tion of the patient in the decision making process of therapeutic
actions, and considering predictive and preventive aspects of the
treatment.1e3,19,20 Asthma, allergic rhinitis (AR), chronic rhinosi-
nusitis (CRS), food allergy (FA) and atopic dermatitis (AD) are
ideally suited for precision medicine, because they represent an
umbrella of different diseases that partially share biological
mechanisms (endotypes) and present similar visible properties
(phenotypes) that require an individualized approach for a better
selection of treatment responders, risk prediction and design of
disease-modifying strategies.3,16,20 The precision in the clinicneeds four main components: an improved disease taxonomy is a
current unmet need because none of the disease endotypes in
allergic diseases are included in the existing taxonomies; full pa-
tient monitoring using novel digital technology and the concept of
endotypes and novel biomarkers is a must; improved under-
standing and common usage of disease phenotypes, endotypes
and biomarkers preferentially at the point of care; and ﬁnally
biomarker and endotype-linked patient care and usage of preci-
sion therapies.1
Longitudinal follow-up of clinical and molecular proﬁles is
essential to conﬁrm the validity of an endotype.21 Participants in
the Childhood Asthma Management Program (CAMP) study were
evaluated 9 and 14 years after they ended the trial. Differences in
clinical characteristics observed between subjects assigned to
different phenotypic clusters persisted into young adulthood and
were associated with differences in molecular signatures for atopy
and asthma control.22
New bioinformatics tools to deﬁne endotypes
Several new approaches are used nowadays to deﬁne an endo-
type, including more accessible tools for human immunopheno-
typing, speciﬁc targeted immune therapies and the application of
omics and new statistical tools. Gene expression proﬁling of airway
samples introduced the deﬁnition of the type-2 asthma endo-
type.23 Novel biomarkers of Th2 inﬂammation are being identiﬁed
in easily accessible non-invasive samples such as serum, exhaled
air, nasal brushing, urine and sputum.24e26 Transcriptomic endo-
types of asthma based on common patterns of gene expression in
the sputum and blood were recently described in a cohort of chil-
dren with asthma and were associated with near-fatal, severe, and
milder asthma.27
There is a shift from investigator-imposed subjective disease
clustering (hypothesis driven) to data-driven disease endotyping
(hypothesis generating). New statistical tools such as supervised
analysis, Latent Class Analysis (LCA), Bayesian Network Analysis
(BNA), Topological Data Analysis (TDA) and several types of
Network Analysis become available. From these tools, supervised
analysis with receiver operating characteristic (ROC) curves and
regression trees can ﬁnd the best predictor from a set of continuous
variables,28 LCA is used to reduce the dimensionality of the data
sets and to group variables into patterns,29 BNA helps to explore
associations between parameters,30 while TDA can identify multi-
dimensional endotypes.31 In a recent study ROC curves identiﬁed
IL-13 and IL-5 as best predictors for blood eosinophilia, followed by
EDN and exhaled NO. In the regression tree model, blood eosino-
philia was best predicted by IL-5. The next important variables
were EDN and eNO.21 The application of LCA integrating sputum
supernatant eicosanoids with quantitative assessment of sputum
cells revealed four distinct asthma classes differing in eicosanoid
pathways.32 In severe asthma, TDA identiﬁed six novel clinic-
patho-biological clusters of underlying disease mechanisms, with
elevated mast cell mediators tryptase, chymase, and carboxypep-
tidase A3.33 BNA separated clinical features from intricately con-
nected inﬂammatory pathways highlighting the expression of YKL-
40 in patients with neutrophilic inﬂammation and the expression
of MMPs in patients with severe asthma.34 Apparently, generalized
usage of these tools will help to better understand the complex
pathophysiology and complex endotypes.
Data-driven models are another type of unbiased approach for
characterization of endotypes. Multivariate regression splines
(MARS) is a robust nonparametric modeling approach that out-
performs other approaches including linear regression modeling,
classiﬁcation trees.35 Non-parametric MARS modeling approach
yields highly accurate classiﬁers of inﬂammatory endotypes in
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Clinical biomarkers and blood gene expression collected from a
stratiﬁed, cross-sectional study of asthmatic and non-asthmatic
children enrolled into The Mechanistic Indicators of Childhood
Asthma (MICA) study were used to construct a data-driven model.
The model proved the interplay between innate and adaptive im-
mune responses, with a dominant role for adaptive immunity in
one group, innate immunity two other groups and a mixed
contribution in the forth group. Metabolic syndrome-induced sys-
temic inﬂammation was an associated factor in three of the four
asthma endotypes. This study suggested underlying mechanisms
linking obesity and asthma through systemic inﬂammation and
common genetic background. The context provided by the clinical
biomarker data was essential in interpreting gene expression pat-
terns and identifying putative endotypes, which emphasizes the
importance of integrated approaches when studying complex dis-
eases.37 In an adult asthma study metabolomic data, genome-wide
genotype, gene expression, and methylation data were used to
construct a Conditional Gaussian Bayesian Network (CGBN). Inte-
grative and metabolic pathway over-representation analyses (ORA)
identiﬁed enrichment of known biological pathways within the
strongest molecular determinants. The CGBN model based on four
SNPs and two metabolites could predict asthma control with an
AUC of 95%. Integrative ORA identiﬁed 17 signiﬁcantly enriched
pathways related to cellular immune response, interferon signaling,
and cytokine-related signaling. Arachidonic acid, prostaglandin E2
(PGE2) and sphingosine 1-phosphate (S1P), in addition to six genes
appeared to drive the pathway results.38 Proteineprotein interac-
tion network (PPIN) provides a new framework to detect genes for
different stages of asthma. By investigating the proteins in stage-
speciﬁc interactions, the study demonstrated that they are more
likely related to asthma, and the functional enrichment analysis
indicated that the pathways enriched in the differential in-
teractions are related to the progress of asthma.39
Creation, harmonization and merging of large datasets will
enable the validation of endotypes on a population level. Ideally,
these large datasets would integrate existing clinical and “omics”
data (e.g., genomic, proteomic, lipidomic, and microbiomic). The
use of harmonized terminology for patient characteristics and
outcomes, of standardized protocols and open access to re-
positories for biospecimen collection are of critical importance.
Type 2 immune response driven complex endotype
Generally, it is considered that a type 2 immune response un-
derlines atopic asthma and allergic rhinitis, as a fundament for the
united airways disease concept.3,40 Type 2 immune response in-
volves Th2 cells, type 2 B cells, group 2 innate lymphoid cells (ILC), a
small fraction of IL-4 secreting NK cells, IL-4 secreting NK-T cells,
basophils, eosinophils and mast cells and their major cytokines.
From a complex network of cytokines, IL-4, IL-5, IL-9 and IL-13 are
mainly secreted from the immune system cells and IL-25, IL-31, IL-
33 and TSLP from tissue cells, particularly epithelial cells41 (Fig. 2).
Both the innate and the acquired immune response contribute to
type 2 immune response endotypes. Th1/Th17 inﬂammatory cells
and non-allergic mechanisms such as environmental factors,
psycho-social stress, activation of metabolic pathways, resident
cells in the remodeled phenotype or epithelial barrier dysfunction
further modulate the proﬁle of type 2-driven inﬂammation.42e46 In
addition, type 2-driven inﬂammation is characterized by a high
cellular plasticity that enables the cells to adapt to a speciﬁc in-
ﬂammatory milieu. Several sub-endotypes might exist within the
type 2 immune response complex endotype such as the IL-5-high,
IL-13-high or IgE-high endotype7 and their preponderance differs
between allergic diseases (Fig. 3).7In asthma, the type 2 immune response endotype has been
related to response to inhaled corticosteroids3,47 and to disease
outcomes, such as exacerbations.48,49 For asthma many targeted
treatments are in various stages of clinical development for pa-
tients with type 2 immune response-driven inﬂammation: anti-IL-
4/IL-13,50,51 anti-IL-4,52 anti-IL-5,53e55 and anti-IgE anti-
bodies,56,57 as well as CRTH2 antagonists58e60 and an endotype
driven approach guided by biomarkers such as blood or sputum
eosinophilia or serum periostin seems to predict treatment
response.
In chronic rhinosinusitis (CRS) with nasal polyposis (NP) there
is good evidence for a type 2 immune response driven endo-
type.61 The eosinophilic pathway driven by IL-5 is prominent,
together with local IgE production and innate immune response
activation, such as ILC type 2 cells. Tissue eosinophilia and evi-
dence of eosinophil activation are closely associated with
remodeling features of CRS, associated mucosal damage and
clinical symptoms.62 A recent study evaluating the inﬂammatory
endotypes of CRS using partition-based clustering showed several
IL-5-positive clusters: a group with moderate IL-5 concentrations,
a mixed CRS with and without nasal polyposis (NP) and increased
asthma phenotype, and a group with high IL-5 levels, an almost
exclusive NP phenotype with strongly increased asthma preva-
lence. In the IL-5 high group, two clusters demonstrated the
highest concentrations of IgE and asthma prevalence, with all
samples expressing Staphylococcus aureus enterotoxin-speciﬁc
IgE.63 Both anti IL-5 and anti IgE targeted interventions showed
clinical efﬁcacy in CRS with NP.64,65 The IL-4/IL-13 pathway seems
similar important for CRS with NP: targeted intervention with
dupilumab on top of nasal steroids for 16 weeks signiﬁcantly
reduced the NP burden.66
Type 2 immune response in AD covers the whole disease
spectrum from background inﬂammation in non-lesional skin to
acute disease ﬂares and to chronic disease, peaking during acute
ﬂares.67e69 IL-4/IL-13 seems to be key drivers since targeted
treatment with dupilumab improved signiﬁcantly the clinical re-
sponses and the AD gene signature in a dose-dependent man-
ner.70e72 Anti IgE treatment seemed less rewarding in AD, although
a subgroup of responders can be identiﬁed by the absence of
ﬁlaggrin mutations and altered lipid metabolite proﬁles with high
levels of various glycerophospholipids.73Non-type 2 immune response driven complex endotype
Non-eosinophilic asthma is a well-documented asthma pheno-
type. Studies in large cohorts, such as the SARP (Severe Asthma
Research Program) cohort, identiﬁed neutrophilic inﬂammation
through induced sputum as an important hallmark of a distinct
cluster of patients with moderate to severe asthma.74 More recent
studies evaluating the molecular signature of the Th2 genes23 or
using unsupervised hierarchical clustering of gene expression pro-
ﬁles in asthma75 reinforce the reality of non-eosinophilic asthma. In
CRS with NP unsupervised cluster analysis showed a distinct cluster
characterized by neutrophilic inﬂammation76 and Th1/Th17 polari-
zation was described for NP sampled from Asian patients.77 Age-
related decline in neutrophil inﬂammation was related to better
postoperative results in elderly patients with non-eosinophilic NP.78
Th22- and Th1-driven inﬂammation is prominent in patients with
the chronic form of AD.67e69
Several data sets support the relevance of multiple non-type 2-
driven molecular sub-endotypes in allergic diseases related to
neutrophilic inﬂammation, Th17 pathway activation, tissue
remodeling and barrier defects, neurogenic inﬂammation with
chemosensory dysfunction (Fig. 4).
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Two major mechanisms leading to non type 2 inﬂammation
have been postulated: the dysregulated innate immune response,
including neutrophil intrinsic abnormalities and the activation of
the IL-17-dependent pathway.79 In addition, type 1 immuneFig. 3. The complex type 2 immune response driven endotype consists of several individual
therapeutic target in asthma validated in major phase III clinical trials leading to regulatory a
in CRS with NP. The IL-4/IL-13 pathway seems similarly important for asthma, CRS with NP
Targeting systemic IgE is a well validated intervention in allergic asthma and new anti-IgE m
rewarding in AD. Local IgE production is a key pathogenic event driving the inﬂammation pr
primary disease phenotype.
Continuous line: type 2 immune response endotypes with a beneﬁcial response to targeted t
evidence relating to disease pathogenesis.
CRS, chronic rhinosinusitis; AD, atopic dermatitis.response, metabolic or epigenetic factors, or the activation of the
epithelial-mesenchymal trophic unit that may lead to extensive
remodeling without any inﬂammation have been identiﬁed as
modulators. The endotyping of the non-type 2 allergic diseases lags
well behind type 2 immune response, and until now, no endotype-
driven interventions have been proven to be effective.pathways with different preponderance in major allergic diseases. The IL-5 pathway is a
pproval of mepolizumab for severe asthma and was targeted in a proof of concept study
and AD: targeted intervention with dupilumab signiﬁcantly reduced symptom burden.
onoclonal antibodies are under clinical development. Anti-IgE treatment seemed less
ocess both in AR and CRS. Up to now no targeted interventions were tested for AR as a
reatment and/or strong evidence for involvement in disease pathogenesis. Dashed line:
Fig. 4. Multiple non-type 2-driven molecular sub-endotypes in major allergic diseases. Growing evidence supports a role for a dysregulated innate immune response promoting
neutrophilic inﬂammation in asthma, rhinitis and CRS. The IL-17 pathway has been related to disease severity in asthma, CRS and AD. Tissue remodeling and barrier defects are
major players modulating the non type-2 immune response in asthma and CRS, while barrier defect is central for all disease phenotypes. The neurogenic inﬂammation pathway
appears of particular importance in rhinitis and AD.
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immune response in neutrophilic asthma, with altered gene
expression of Toll like receptors and increased expression of genes
from the IL-1b and TNF-a/nuclear factor-kB pathways,80 phenotype
switch and enhanced neutrophil chemotaxis and survival in the
airways, impairment in anti-inﬂammatory mechanisms and in
pathogen recognition and destruction processes and increased
protease activity. The signature of non-eosinophilic asthma in-
cludes three genes involved in innate immune response: IL-1b,
alkaline phosphatase tissue-nonspeciﬁc isozyme and CXCR2.81
In an experimental model of Th1/neutrophil-predominant
asthma, TNFa reduced the responsiveness to steroids and neutrali-
zation of TNFa using etanercept restored glucocorticoid sensitivity.82
Recently, the TNF superfamily member, LIGHT, has been implicated
as a mediator in asthmatic airway inﬂammation. Human bronchial
epithelial cells express the receptor for LIGHT, the lymphotoxin b
receptor (LTbR) and upon stimulation with LIGHT release IL-6,
oncostatin M, MCP-1, growth-regulated protein a and IL-8.83
In non-eosinophilic asthma blood neutrophils release signiﬁ-
cantly higher levels of IL-8 at rest. Microarrays demonstrated
expression proﬁles that were signiﬁcantly distinct from eosino-
philic asthma: 317 genes were signiﬁcantly altered in resting neu-
trophils, including genes related to cell motility and regulation of
apoptosis.84 Persistent elevation of airway neutrophils due to
impaired efferocytosis was also described. Galectin-3 (gal-3) is
signiﬁcantly reduced in neutrophilic asthma compared with
eosinophilic and paucigranulocytic asthma. In addition, patients
with neutrophilic asthma have impairment in anti-inﬂammatory
ratio of gal-3/gal-3 binding protein and IL-1RA/IL-1b.85
Altered pathogen recognition and destruction processes are
present with macrophage efferocytosis impaired in non-
eosinophilic asthma to a similar degree as in COPD.86 A low num-
ber of neutrophils or the presence of a type of neutrophils with
compromised antimicrobial activity was related to the formation of
bioﬁlms in CRS.87
The increased activity of neutrophil elastase is in direct corre-
lationwith the levels of interleukin-8 and neutrophils.88 In a subset
of chronic obstructive lung disease (COPD) patients the tripeptide
matrikine proline-glycine-proline (PGP) seems to play a role. Azi-
thromycin and roﬂumilast have been shown to reduce acute ex-
acerbations of COPD and recent evidence has linked both of these
agents to modulation of the PGP/neutrophil pathway in concert
with this exacerbation reduction, thus supporting the PGP/neutrophil pathway as a new target for the neutrophilic airway
inﬂammation.89
IL-17 and neutrophilic endotype
Through the induction of cytokines and chemokines IL-17 is a
major driving force for the recruitment of neutrophil granulocytes
in the lungs and their activation directly through CXCL8 production
or indirectly by inducing the production of IL-6, G-CSF and GM-CSF,
IL-8, CXCL1, and CXCL5 by airway epithelial cells. Although Th17
cells represent a core source of IL-17, a newly identiﬁed population
of innate lymphoid cells (ILCs) is also able to produce IL-17.90,91 IL-
17e producing ILC3s express CC chemokine receptor 6, produce IL-
17 and sometimes IL-22, and are central to the development of
asthma in obese mice. Increased numbers of this subset of cells
have been found in the bronchoalveolar lavage (BAL) ﬂuid of obese
individuals with severe asthma.92
A likely role of IL-17 in neutrophilic asthma is suggested by the
signiﬁcant association between IL-17 and other diseases with un-
derlying neutrophilic inﬂammation, such as psoriasis, and by the
efﬁciency of IL-17-targeted therapies in these diseases.93 The link
between neutrophilic inﬂammation and Th17 immunity is well
established in mousemodels of asthma, where it has been linked to
the development of airway hyperreactivity (AHR) and remodel-
ing.94,95 Human data are accumulating, however a cause and effect
relationship between IL-17 production and neutrophilic asthma has
not been demonstrated and targeted interventionwith brodalumab
(an anti IL-17 receptor monoclonal antibody) did not show a sig-
niﬁcant treatment effect.96 A strong correlation between IL-17 and
neutrophils was established in induced sputum and blood.97,98 IL-
17 has been linked to remodeling, AHR, asthma severity and
inﬂammation.99e101 In the Clinical Asthma Research Association
cohort study, patients with non-allergic asthma showed very
distinctly IL-17-shifted proinﬂammatory immunity, promoting
neutrophil inﬂammation and less functional Treg cells. In parallel,
expressions of anti-inﬂammatory IL-37, proline-serine-threonine
phosphatase-interacting protein 2, the neutrophil-associated
genes CD93, triggering receptor expressed on myeloid cells 1, and
regulator of G-protein signaling 13 were increased.102 In a recent
study however Th17 cells and gd17 cells were not associated with
asthma, even in the severe neutrophilic forms. Instead, mucosal
associated invariant T (MAIT)-cell frequencies were strikingly
reduced in asthma compared with health, both in sputum and in
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tory T cells were also reduced.34
Th17 cells are resistant to glucocorticoid-induced apoptosis and
cytokine suppression, at least in part due to high levels of BCL-2.103
These ﬁndings support a role of Th17 cells in steroid-resistant (SR)
endotypes of asthma, chronic rhinosinusitis or atopic dermatitis.
The IL-17 pathway was related to decreased corticosteroid sensi-
tivity, also a characteristic of neutrophilic asthma.104 Patients with
SR asthma produced signiﬁcantly increased IL-17A and IFN-g levels
compared to steroid sensitive (SS) asthma. Production of IL-17Awas
inversely and production of IL-13was positively associatedwith the
clinical response to prednisolone. Oral calcitriol signiﬁcantly
improved dexamethasone-induced IL-10 production in vitro while
suppressing dexamethasone-induced IL-17A production. This effect
mirrored the previously demonstrated improvement in clinical
response to oral glucocorticoids in calcitriol-treated patients with
SR asthma. These data identify immunologic pathways that likely
underpin the beneﬁcial clinical effects of calcitriol in patients with
SR asthma and suggest strategies for identifying vitamin D re-
sponders in asthma.105
Inﬂammatory cell expression of IL-9 and IL-17C is increased in
CRS, especially in association with NP, asthma and atopy.106 Th17
cytokines (IL-17, IL-22, and IL-26) have been shown to induce a
signiﬁcant disruption of the epithelial barrier, in contrast to the
application of interferons and of Th1 or Th2 cytokines who did not
affect the mucosal barrier function.107 IL-17 receptor B levels are
increased in immune cells of patients with NPs compared to con-
trols and IL-25 expression is up-regulated in NP mucosa from pa-
tients with CRS with NPs compared with control subjects and those
with CRS without NPs. IL-25mRNA expression positively correlated
with the expression of T-box transcription factor, RAR-related
orphan receptor C, GATA3, eosinophil cationic protein, TGF-b1,
and TGF-b2. In the murine NP model IL-25 was also more abundant
compared with controls mice, and similar correlations with in-
ﬂammatory markers were observed. Anti-IL-25 treatment reduced
the number of polyps, mucosal edema thickness, collagen deposi-
tion, inﬁltrationwith inﬂammatory cells, and expression of IL-4 and
IFN-g, CCL11, CXCL2, ICAM 1 and VCAM 1.108
Th17 cells are increased in both skin52e54 and blood of patients
with AD.109 In amousemodel of AD deﬁciency of ﬁlaggrin appeared
to be a driver of increased peripheral levels of Th17 cells. The au-
thors hypothesized that this increase must be acquired as periph-
eral Th17 cells were found only in adult mice indicating
involvement of exogenous factors.110Neurogenic inﬂammation
Neurogenic rhinitis is a particular endotype characterized by a
relative overexpression of transient receptor potential channels on
trigeminal nerves and high concentrations of substance P and
neurokinins and is linked to gustatory rhinitis, rhinitis of the
elderly, and idiopathic rhinitis with nasal hyperreactivity.111 The
serum level of the nerve growth factor (NGF) is signiﬁcantly higher
in AD compared to controls, and correlates with the severity of itch,
erythema, scale/xerosis and eosinophil count.112 There is increased
expression of NGF in the lesional compared to non-lesional AD and
the number of mast cell-nerve ﬁbers (NF) contacts correlates with
SCORAD and itch in lesional skin. Nicotinic acetylcholine receptor
a7 mRNA, a marker for the non-neuronal cholinergic system
(NNCS) was signiﬁcantly lower in lesional AD skin at baseline. After
the stress test NF numbers dropped in lesional AD as did their
contacts with mast cells and NGF þ NF now correlated with
SCORAD andmast cell-NF contacts with itch in non-lesional skin. At
the same time, expression of secreted mammal Ly-6/urokinase-type plasminogen activator receptor-related levels (a marker for
NNCS activation) increased in lesional AD skin.113
The mixed type 2/Th17 endotype
The mixed Th17/Th2 endotype is not rare in asthma, CRS or AD.
Th2 cells can differentiate into dual-positive Th2/Th17 cells114 and
these cells were identiﬁed in the BAL ﬂuid of asthmatic patients and
related to glucocorticoid resistance in vitro and airway obstruction
and hyperreactivity.43 In CRS IL-25 receptor (IL-17RB)-expressing
Th2 effector cells were identiﬁed in NP tissue but not the healthy
nasal mucosa or periphery, while abundant IL-17-producing T cells
were observed in both healthy nasal mucosal and polyp pop-
ulations, thus suggesting that the Th17 response might be impor-
tant in healthy nasal mucosal immune homeostasis and the NP
inﬂammation and remodeling occurs within the mixed endo-
type.115 A non-type 2 immune response mixing Th1, Th17 and Th22
driven inﬂammation and epithelial dysfunction is also described for
AD in non-lesional skin and in the chronic remitting-relapsing form
of the disease.67e69
The relationship between Th17 and type 2 immune response is
highly complex. An interesting model suggests that IL-17 produced
by gd T cells and by Th17 cells in response to injured epithelium
enhances the production of IL-4 and IL-13 from ILC2 and Th2 cells,
which acts as a negative feedback loop shutting down further IL-17
production and neutrophilia.116 Conversely, IL-4 and IL-13 may
amplify Th17 responses by up-regulating CD209a expression on
dendritic cells.117 When the type 2 response fails to fully suppress
the IL-17 response, or further promotes it, excessive tissue damage
can occur. Understanding what regulates the IL-17eIL-4/13 feed-
back loops will provide invaluable insight into situations in which
IL-17 exacerbates type 2 inﬂammation.
In a cross-sectional study of asthmatics of varying severity endo-
bronchial tissue gene expression analysis revealed three major
patient clusters: Th2-high, Th17-high, and Th2/17-low. In individ-
ual patient samples, Th2-high and Th17-high patterns were
mutually exclusive and their gene signatures were inversely
correlated and differentially regulated by IL-13 and IL-17A. This
dichotomous pattern was further investigated in a preclinical
model of allergen-induced asthma. Neutralization of IL-4 and/or IL-
13 resulted in increased Th17 cells and neutrophilic inﬂammation
in the lung. Neutralization of both IL-13 and IL-17 protected mice
from eosinophilia, mucus hyperplasia, and airway hyperreactivity
and abolished the neutrophilic inﬂammation, suggesting that
combination therapies targeting both pathways may maximize
therapeutic efﬁcacy across a patient population with a mixed Th2/
Th17 endotype.118
Chitinases and chitinase-like proteins (CLPs) may be an impor-
tant link between type 2 immunity and IL-17. Acting as danger-
associated molecular patterns CLPs release IL-1 with IL-17 pro-
duction by innate gd T cells, which in turn drives a type 2 response.
Subsequently type 2 cytokines induce even more CLP expression,
which likely further contribute to repair. Additionally, CLPs can
promote Th2 differentiation and suppress IFNg, further promoting
type 2 immunity.119 Furthermore neutrophils can switch to an N2
phenotype, contributing to the pool of IL-13, which in addition to
IL-4, promotes activation of macrophages limiting further injury
and promoting repair.120 IL-33 is a co-factor that cooperates with
IL-17A to exacerbate AHR by enhancing neutrophilic inﬂammation
via CXCR2 signaling. Furthermore, CXCR2 signaling derived Th2
responses are enhanced.118 In patients with CRS with NP IL-25 and
IL-33 interact locally with IL-17RBþST2þ polyp T cells to augment
Th2 responses.115 IL-17 signiﬁcantly increases MUC5B mucin
expression, while IL-13 additionally induces signiﬁcant goblet cell
hyperplasia and MUC5AC mucin expression in CRS with NP. IFN-g
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ciliary beat frequency.121Unmet needs and perspectives
To emphasize the importance of endotyping of diseases, dis-
covery of biomarkers, it will be good to quote a pioneer in precision
medicine, Sir John Bell, Professor of Medicine at Oxford University,
and Chairman of the Ofﬁce for the Strategic Coordination of Health
Research: “The best example of precision medicine in my opinion
does not come from cancer, it comes from asthma. For this condi-
tion, we have gonemore than 20 years without a newdrug, because
the disease was not deﬁned very well.” (http://www.pharmaﬁle.
com/news/.) As said, successful management of patients with se-
vere asthma and allergic diseases continues to be a major unmet
need. One of the barriers to successful management is the hetero-
geneity of the diseases with different phenotypes and endotypes. A
revised paradigm for disease management, that entails categori-
zation of patients via use of endotypes and multiomic biomarkers
for prescribing targeted therapy, will replace the “one size ﬁts all”
approach to allergic diseases. The success of cytokine inhibition
deﬁning the hierarchical position of distinct cytokines in allergic
diseases pathogenesis with the description of meaningful clinical
endotypes hold the promise to transform the therapeutic landscape
in allergic diseases in a precision based fashion.
The precision medicine initiative recently announced the need
to move the ﬁeld of precision medicine more rapidly into clinical
care. As currently structured, it will primarily fund efforts in cancer
genomics with longer-term goals of advancing precision medicine
to all areas of health. This focused effort provides scientists, clini-
cians, and patients within the allergy community an opportunity to
work together boldly to advance clinical care; the community
needs to be aware and engaged in the process as it progresses.
To move beyond a select few genes/drugs, the successful
adoption of pharmacogenomics into routine clinical care and
development of computational approaches and tools to effectively
integrate multidomain data (such as cognitive IT-systems) are ur-
gently needed for the development of newly targeted treatments.
Real-time databases for molecular proﬁling data could become a
pragmatic solution to several knowledge management problems in
the practice and science of precision medicine. “Interventional
informatics” approach can substantially improve human health and
wellness through the use of data-driven interventions at the point
of care of broader population levels. The collaborative medicine
approach with open access to research databases worldwide will
speed the discovery of new targets.Conclusion
The endotype driven approach implementing multiomics, bio-
markers and computation approaches to big data analysis is slowly
making its way into the precision management of allergic diseases.
Several disease complex endotypes can be identiﬁed for asthma,
AR, CRS and AD. Sub-endotypes exist within complex endotype
umbrella, and their preponderance differs between allergic dis-
eases. Both the innate and the acquired immune response
contribute to type 2 and non type-2 immune response endotypes
and non-allergic mechanisms such as environmental factors,
psycho-social stress, activation of metabolic pathways, resident
cells in the remodeled phenotype or epithelial barrier dysfunction
further modulate the proﬁle of the inﬂammation.
The recent focus on precision medicine opens new opportu-
nities for the allergy community to advance in the clinical care of
allergic patients in a cost-efﬁcient and equitable way.Acknowledgments
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